DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Baraclude (Entecavir) - Summary

 

-- advertisement --

WARNINGS

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals.

Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted (see WARNINGS).

 

BARACLUDE SUMMARY

Baraclude™
(entecavir)
Baraclude™ (entecavir) Tablets
Baraclude™ (entecavir) Oral Solution

BARACLUDE™ is the tradename for entecavir, a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV).

BARACLUDE (entecavir) is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

This indication is based on histologic, virologic, biochemical, and serologic responses after one year of treatment in nucleoside-treatment-naive and lamivudine-resistant adult patients with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease and on more limited data in adult patients with HIV/HBV co-infection who have received prior lamivudine therapy.

BARACLUDE NEWS HIGHLIGHTS

Media Articles Related to Baraclude (Entecavir)

Selecting Anti-Hepatitis B Virus Agents For Drug-Resistance Patients
Source: Liver Disease / Hepatitis News From Medical News Today [2008.09.25]

more>>

Published Studies Related to Baraclude (Entecavir)

Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients. [2008.06.12]

Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. [2008.01]

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. [2007.11]

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. [2007.03]

[Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment.] [2007.01]

more>>

Clinical Trials Related to Baraclude (Entecavir)

Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis [Enrolling by invitation]

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-Resistant Virus [Recruiting]

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B [Recruiting]

Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B [Not yet recruiting]

Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders [Recruiting]

more>>

Page last updated: 2008-09-25

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008